Evaluation of a Risk-Stratified National Breast Screening Programme in the United Kingdom: An updated cost-effectiveness analysis
Authors: Wright Stuart J , Rogers Gabriel , Gray Ewan , Donten Anna , McWilliams Lorna , French David P , Evans D Gareth , Payne Katherine 
Published: April 2024

AbstractStudy objectiveTo update a published early economic evaluation of exemplar risk-stratified national breast screening programmes (stratified-NBSP).MethodAn existing validated decision-analytic model, using discrete event simulation (the ‘Gray-model’), was used to structure the pathways for 3 stratified-NBSP (risk-1; risk-2; risk-3) compared with the current NBSP in the United Kingdom (UK-NBSP), biannual screening, and no screening. The updated model is called MANC-RISK-SCREEN and assumes a life-time horizon, the UK health service perspective to identify costs (using £; 2022) and measures health consequences using life-years and Quality Adjusted Life Years (QALYs). The original data sources used for the Gray-model were assessed for current relevance and updated where feasible. Updated data sources included: cancer and all-cause mortality; breast cancer incidence; breast cancer risk data; tumour staging; recall rate; mammographic sensitivity by breast density group; costs; and utilities. Model parameter uncertainty was assessed using Probabilistic Sensitivity Analysis (PSA) and one-way sensitivity analysis.ResultsThe base case analysis, supported by PSA, suggested that there was always a risk-stratified approach to breast cancer screening that was superior to universal screening. In the base case analysis, a strategy of dividing women into three equal groups based on risk was the most cost-effective. In the PSA, a strategy based on that used in the BC-PREDICT study was the most cost-effective. There was uncertainty in whether the addition of reduced screening for women at lower risk was cost-effective.ConclusionThe results of this study suggest that risk-stratified approaches to breast cancer screening are more cost-effective than both 3-yearly and 2-yearly universal screening.HighlightsA published early decision-analytic model-based cost-effectiveness analysis, using discrete event simulation (the ‘Gray model’), produced indicative results suggesting all included exemplars of a stratified national breast screening programme (stratified-NBSP) were cost-effective compared with no screening but a fully incremental analysis indicated only risk-based stratified-NBSP were cost-effective.This study uses a subsequently validated version of the Gray-model to produce a cost-effectiveness analysis with an updated model called MANC-RISK-SCREEN using revised descriptions of the relevant stratified-NBSP and new values for cancer and all-cause mortality; breast cancer incidence; breast cancer risk data; tumour staging; recall rate; mammographic sensitivity by breast density group; costs; and utilities.This analysis builds on the indicative estimates of the healthcare costs and health consequences of stratified-NBSP and suggests, with the current level of evidence, they are a cost-effective use of the NHS budget in the United Kingdom but uncertainty remains in the value of reducing screening for those at lower risk.